Drug Discovery
ByHow Might Trump’s Strategic Healthcare Proposal Impact Innovation and Affordability?
January 22, 2026 — Global — BioNexAI Market Insights reports that U.S. President Donald J. Trump has introduced…
How Will Hippocratic AI Leverage Grove AI to Accelerate Trial Efficiency and Patient Engagement?
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
Is Novartis Bolstering Its Radioligand Oncology Pipeline at JPM 2026 with a Radioligand Peptide Program Acquisition?
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a global license and…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026 a Defining Move in the Obesity and Cardiometabolic Race?
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients Served Amid Gene Therapy Market Reality Check
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox)…
Boehringer’s Hernexeos Secures Record 44-Day FDA Nod via Priority Voucher—76% ORR in HER2-Mutant NSCLC Frontier
Published by BioNextAI Media – Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets) snagged ultra-fast FDA accelerated approval in just 44 days…
